secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-06-12T18:20:32+00:00
Accession:  0001140361-26-025050
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis olezarsen OLE data: liver fat returns toward baseline after 24 months; 90%+ retention
--------------------------------------------------------------------------------

- Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of olezarsen 80 mg in CORE-OLE study of severe hypertriglyceridemia.
- Patients transitioning from 50 mg to 80 mg showed less pronounced HFF changes; safety profile remained favorable with longer treatment.
- Over 90% of eligible patients from CORE/CORE2 studies enrolled and remained in the open-label extension.
- Data presented at National Lipid Association Scientific Sessions in Chicago on June 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/0001140361-26-025050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/ef20076110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-025050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer